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Objective: Elevated inflammatory cytokine levels have been implicated in the pathogenesis of non-healing chronic venous
insufficiency (CVI) ulcers. The goal of this study was to determine the protein levels of a wide range of inflammatory
cytokines in untreated CVI ulcer tissue before and after 4 weeks of high-strength compression therapy. These levels were
compared to cytokines present in healthy tissue.
Methods: Thirty limbs with untreated CVI and leg ulceration received therapy for 4 weeks with sustained high-
compression bandaging at an ambulatory wound center. Biopsies were obtained from healthy and ulcerated tissue before
and after therapy. A multiplexed protein assay was used to measure multiple cytokines in a single sample. Patients were
designated as rapid or delayed healers based on ulcer surface area change.
Results: The majority of pro-inflammatory cytokine protein levels were elevated in ulcer tissue compared to healthy tissue,
and compression therapy significantly reduced these cytokines. TGF-1 was upregulated in ulcer tissue following
compression therapy. Rapid healing ulcers had significantly higher levels of IL-1, IL-1, IFN-, IL-12p40, and
granulocyte macrophage colony stimulating factor (GM-CSF) before compression therapy, and IL-1 Ra after therapy.
IFN- levels significantly decreased following therapy in the rapidly healing patients.
Conclusion: CVI ulcer healing is associated with a pro-inflammatory environment prior to treatment that reflects
metabolically active peri-wound tissue that has the potential to heal. Treatment with compression therapy results in
healing that is coupled with reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokine
IL-1 Ra. (J Vasc Surg 2009;49:1013-20.)
Clinical Relevance: This data suggests that cytokines may provide targets in which topical therapeutic inhibition or
promotion at appropriate time points in the healing process may provide novel therapeutic approaches to the healing of
CVI ulcers.In the United States, chronic venous insufficiency
(CVI) is the most common etiology of chronic non-healing
lower extremity ulcers, estimated to be responsible for over
75% of cases. Though rarely a cause of limb amputation,
these chronic wounds result in significant morbidity, pain,
and are estimated to cause more than 2 million lost work
days per year.1 These ulcerations negatively impact a per-
son’s quality of life, especially if delayed healing is experi-
enced.2 The majority of patients with leg ulcers and asso-
ciated venous insufficiency will experience progressive
healing when treated with sustained limb compression of
30 mm Hg or greater,3-5 but healing typically requires 3-6
months of treatment or longer. Also, a subset of patients
experience delayed or no healing despite receiving medical
treatment.6-8
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Vascular Surgery.doi:10.1016/j.jvs.2008.11.049Previous studies have identified up-regulation of vari-
ous pro-inflammatory cytokines in fluid collected from
venous leg ulcers. It has been hypothesized that chronic
venous hypertension results in an inflammatory state that is
responsible for poor ulcer healing.9,10 Although compres-
sion therapy results in healing of most venous leg ulcers, the
mechanism responsible for this effect is not well defined.
Historically, cytokine protein levels have been quanti-
fied separately. Luminex multiplex technology allows for
the simultaneous evaluation of multiple cytokines in a
single sample. Microspheres, which are dyed beads coated
with a specific capture antibody, are added to a sample. The
cytokines of interest are captured by the microspheres.
Fluorescent tagged detection antibodies are added, and
samples are fed through a flow cytometer. A dual laser
excites the internal dyes that identify each microsphere
particle (cytokine of interest) and reads the quantity of the
fluorescent detection antibodies, which are in direct pro-
portion to the bound cytokine. This technology gives the
advantages of higher throughput, smaller sample volume,
and improved sensitivity. Other researchers have used mul-
tiplexed immunoassays to measure cytokines in various
bodily fluids.11-13
The main study goal was to quantify both pro- and
anti-inflammatory levels in healthy and CVI ulcer tissue
before and after sustained compression therapy using a
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tory markers related to ulcer healing status. We hypothesized
that pro-inflammatory levels would be elevated in venous
ulcerswith associated low levels of anti-inflammatory cytokine
levels compared to healthy tissue. Following compression
therapy, ulcer tissue was expected to demonstrate cytokine
levels similar to the healthy tissue pattern. Delayed healing
ulcers would theoretically have continued elevation of pro-
inflammatory levels.
METHODS
Clinical protocol. Enrolled patients were 18 years of
age or greater with onset of lower extremity ulceration and
edema (CEAP class 6, primary or secondary etiology)
within 6 months of study participation per history, physical
exam, and referring physician documentation. Only pa-
tients that had not received previous compression therapy
were included. Abnormal venous function and CEAP cri-
teria were examined using duplex ultrasonography scan and
air plethysmography. Patients that did not meet criteria for
venous insufficiency on both studies were excluded. ADuplex
ultrasonography scan was performed with patients in a stand-
ing position using an automatic inflation/deflation cuff sys-
tem (Hokanson E20 Rapid Cuff Inflator and AG101 Cuff
Inflator Air Source, Issaquah, Wash), and CVI was defined
as the presence of reflux in the deep or superficial veins of
0.5 seconds.14 An abnormal venous filling index as as-
sessed by air plethysmography was 2 mL/second.15
Exclusion criteria included an Ankle to Brachial Index
(ABI) of less than 0.7, congenital venous insufficiency,
previous treatment with any form of high-strength com-
pression bandaging, active systemic infection, severe immu-
nocompromised state, dressing allergy, use of an investiga-
tional drug, history of vasculitis, or poor medical compliance.
This protocol was approved by the University of North
Carolina at Chapel Hill’s Institutional Review Board and
Independent Ethics Committee. Informed consent was
obtained from all patients prior to study enrollment.
Wounds were debrided, and a 3-layer or 4-layer com-
pression bandage system (Profore lite or Profore, Smith &
Nephew, Hull, United Kingdom) was applied over a poly-
urethane foam primary dressing. Dressings and compres-
sion bandages were changed weekly. Wounds were photo-
graphed at the initial and subsequent visits.
Planimetry, which used tracings of the ulcer perimeter,
was performed weekly using the Visitrak Digital system
(Smith & Nephew) to determine wound surface area
changes.16 Previous studies of venous ulcer healing with
compression therapy have reported that the percentage
change in wound area between baseline and 3 to 4 weeks of
treatment is predictive of eventual healing. Kantor and
Margolis17 found that improvement at 4 weeks was predic-
tive of eventual healing and Phillips et al18 reported that a
reduced wound size of 40% at 3 weeks of treatment was
predictive of complete healing at 12 weeks of treatment.
Based on these studies, we chose to treat study patients with
weekly compression bandaging for 4 weeks at which time
healing progress and repeat tissue analysis was performed.Patients who had at least a 40% reduction in ulcer surface area
at 4 weeks were designated as rapid healers and those who
healed less than 40% were designated as delayed healers.
Tissue sample collection. Prior to biopsy, 1% lido-
caine was injected for local anesthesia. Full thickness punch
biopsies 6 mm in diameter and 2-3 mm in depth were
obtained from the wound tissue adjacent to intact peri-
ulcer skin and the ipsilateral medial thigh (healthy sample)
using a trephine before the initiation of therapy. After 4
weeks of sustained compression therapy, the ulcer biopsy
was repeated. Following sample collection, the tissue was
flash frozen. Samples were kept at80°C until homogeni-
zation was performed. Immunohistochemistry was not per-
formed due to the limited biopsy size.
Protein sample preparation. Tissue was weighed and
homogenized using a Tissue-Tearor (Biospec Products Inc,
Bartlesville, Okla) homogenizer in a buffer of Dulbecco’s-
Phosphate Buffered Saline (Sigma, St Louis, Mo) and an
ethylenediaminetetraacetic acid (EDTA) free protease in-
hibitor cocktail (Cat. #P8340 Sigma). A total of 0.5 mL of
buffer was added for each 30 mg of tissue sample. The
homogenate was centrifuged (15,000 g  10 minutes at
4°C), and the supernatant total protein concentration was
determined using a bicinchoninic protein assay kit (Pierce,
Rockford, Ill).19 Cytokine protein levels were normalized
to total protein amount.
Protein assays. Previous studies have validated the use
of a multiplex assay for simultaneous measurement of mul-
tiple cytokines in various bodily fluids and cell culture.20-22
The proceeding protein quantification methods were vali-
dated for use with tissue homogenate using both spike and
recovery and dilution curve analysis by our group, and
similar results have been published.23 Assays (n  30 ulcer
tissue, n  23 healthy tissue) were performed in duplicate.
Protein levels of 22 cytokines were determined simulta-
neously in a single sample using the Luminex xMAP system
and a commercial assay kit (Millipore, Billerica, Mass). The
manufacturer’s instructions were followed, and samples
were diluted with the kit’s calibrator diluent to a total
protein concentration of 250 g/mL. Samples were read
by a Luminex 100 dual laser apparatus (Luminex Corp,
Austin, Tex) with StarStation v2.0 software (Applied Cy-
tometry Systems, Sacramento, Calif).
TGF-1 protein levels were measured using ELISA kits
(R&D Systems, Minneapolis, Minn) per the manufacturer’s
protocol, as TGF-1 was not available as a part of the
multiplexed panel. The ELISA requires a larger tissue sam-
ple volume compared to the multiplex analysis; thus, not all
biopsies were studied due to tissue sample size limitations
(n  10 ulcer tissue, n  7 healthy tissue). Results were
read on a MicroQuant plate reader with KCJunior v1.41
software (both Biotek Instruments, Winooski, Vt).
Statistical analysis. Statistical comparisons were made
using SAS v9.1 (SAS Institute Inc, Cary, NC). Statistical
significance was set at P  .05, and measurements are
presented asmeans standard deviations. One way analysis
of variance (ANOVA) for repeated measures was used to
detect differences between healthy tissue and before ther-
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measures. These models take into account that multiple
responses are coming from the same participant. Because
Wilks’ Lambda, Pillai’s Trace, Hotelling-Lawley Trace, and
Roy’s Greatest Root were all in lock-step agreement
throughout (due to two groups in the ANOVA), the F
statistic is reported. Comparisons between cytokine values
in rapid vs delayed healers were performed using both
parametric and non parametric methods. Subjects were
divided into these groups based on whether or not the ulcer
surface area change was more or less than 40% at 4 weeks of
treatment. Modified t tests comparing the means of cyto-
kine levels in these two groups were performed. The mod-
ification was utilized because the comparisons were not
made between two homogenous groups. To confirm sig-
nificance, non parametric tests were conducted using Wil-
coxon’s rank sum test.
RESULTS
Patient demographics. Thirty-three patients with 34
limbs affected with new untreated ulcers were enrolled in
the study. Two were screen failures due to a lack of venous
insufficiency on duplex scan studies and 1 was found to
have an ABI0.7. One patient was unable to comply with
compression treatment leaving 30 limb ulcers for analysis.
Patient demographics and co-morbidities are listed in Table I.
CEAP criteria for venous insufficiency etiology, anatomy,
and pathophysiology are provided in Table II. The average
initial ulcer size was 21.5  26.8 cm2. After 4 weeks of
treatment, 2 ulcers were completely healed, and 3 ulcers
had enlarged. Half of the ulcers healed at least 40% with
4 weeks of treatment, and the average ulcer size de-
creased by 54%.
Cytokine protein levels. Twenty-two cytokines were
measured using a multiplex assay. Six of the 22 cytokines
(IL-2, -5, -7, -12p70, -15, and -17) had either undetect-
able tissue measurements or no statistical significance when
comparing healthy and ulcer tissue before and after com-
pression therapy. The significant cytokines measured using
the Luminex xMAP system and TGF-1 are reported in
Table I. Patient demographics
Number Percentage
Mean age 57.9  16.4 years
Females 20 68.9
Hypertension 9 31
ABI less than 0.9 1 3.4
History of DVT 17 58.6
Diabetes 7 24.1
Hypercoagulable state# 2 6.9
Cardiac disease* 7 24.1
ABI, Ankle brachial index; DVT, deep vein thrombosis.
#Per patient report/documentation. Not routinely measured by our group
in CVI ulcer patients.
*Congestive heart failure, coronary artery disease, atherosclerosis, myocar-
dial infarction, dysrhythmia.Table III.Cytokines in healthy tissue compared to ulcer tissue
before compression. Table IV lists the cytokines demon-
strating a significant difference between concentrations in
healthy tissue compared to ulcer tissue prior to compres-
sion therapy. All of these proteins demonstrated signifi-
cantly higher concentrations in ulcer tissue than in healthy
tissue, with the exception of IL-1	.
Cytokines in ulcer tissue before compression com-
pared to after compression. Table V lists the cytokines
demonstrating a significant difference between concentra-
tions in ulcer tissue before compared to after 4 weeks of
compression therapy. All of the listed proteins demon-
strated significantly higher concentrations in ulcer tissue
before compression therapy with the exception of TGF-1
which increased significantly in ulcer tissue after compres-
sion for 4 weeks.
Association of cytokines and ulcer healing status.
Cytokine levels in ulcer tissue were studied to determine
whether they were able to predict rapid (40% or greater
reduction in ulcer surface area) or delayed (less than 40%
reduction in ulcer surface area) wound healing after 4 weeks
of treatment. Table VI summarizes the findings. Prior to
compression therapy, ulcers with higher levels of IL-1	,
IL-1, IFN-
, IL-12p40, and granulocyte macrophage
colony stimulating factor (GM-CSF) were more likely to be
rapid healers. After 4 weeks of compression, ulcers with
higher levels of IL-1 Ra were also more likely to be rapid
healers. Total change in IFN-
 levels was predictive of
healing. Protein levels before and after compression for the
cytokines demonstrating significant associations with heal-
ing are illustrated in the Fig. The relationship between
TGF-1 levels and ulcer healing could not be determined
due to an insufficient number of measurements.
DISCUSSION
This study reports for the first time, to our knowledge,
the relationship between cytokine protein levels before and
after compression therapy in venous leg ulcers and healthy
tissue. Amultiplexed assay provided simultaneousmeasure-
ments of cytokines in a single tissue homogenate sample.
Although the pathogenesis of venous insufficiency
leading to ulceration is likely multi-factorial, our results
indicate that specific inflammatory mediators are associated
Table II. CEAP criteria
Number Percentage
Etiology
Primary 8 27
Secondary 22 73
Anatomy
Deep venous reflux 12 40
Superficial venous reflux 4 13
Deep and superficial reflux 14 47
Pathophysiology
Reflux only 21 70
Reflux and obstruction 9 30with time- and pattern-dependent healing progression. It
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inflammatory environment is likely required in the early
stages of wound repair. Several authors have argued that
the initial inflammatory response to injury likely programs
the end of inflammation through ‘pro-resolution signaling
networks’, including lipid mediator classes.24,25 Specific to
wound healing, the importance of the initial inflammatory
phase has been noted in several studies, as a paucity of
Table III. Cytokine means  standard deviations (levels e
Healthy tissue
Cytokine N Mean SD N
IL-1	 23 2.59 3.00 30
IL-1 23 0 0 30
IL-1 Ra* 23 172.87 414.19 30
IL-4 23 0.01 0.02 30
IL-6 23 0 0.01 30
IL-8 23 0.03 0.03 30
IL-10* 23 0.01 0.02 30
IL-12p40 23 0.14 0.27 30
IL-13 23 0.02 0.02 30
G-CSF 23 0 0.02 30
GM-CSF 23 0 0.01 30
MCP-1 23 0.11 0.18 30
IFN-
 23 0.01 0.02 30
TNF-	 23 0 0 30
MIP-1	 23 0.05 0.07 30
MIP-1 23 0.12 0.07 30
TGF-1* 7 0.10 0.04 10
SD, Standard deviation; N, number; G-CSF, granulocyte colony-stimulatin
*Anti-inflammatory.
Table IV. Cytokines demonstrating significant
differences between healthy tissue and ulcer tissue before
compression therapy (pg/ug protein). All cytokines,
except TGF-1, n  23. TGF-1 n  7
Healthy Before therapy
Cytokines Mean (SE) Mean (SE) F-statistic
P
value
IL-1	 2.59 (0.61) 0.58 (0.16) 10.15 .004
IL-1 0.004 (0.001) 0.13 (0.05) 7.86 .01
IL-4 0.005 (0.003) 0.02 (0.01) 4.56 .044
IL-6 0.004 (0.002) 0.99 (0.16) 39.54 0
IL-8 0.03 (0.01) 16.57 (4.87) 11.53 .002
IL-10* 0.013 (0.004) 0.04 (0.01) 8.30 .008
IL-12p40 0.14 (0.05) 1.75 (0.37) 17.35 0
IL-13 0.02 (0.01) 0.04 (0.01) 5.95 .023
G-CSF 0.005 (0.003) 0.22 (0.04) 25.98 0
GM-CSF 0.003 (0.001) 0.07 (0.01) 22.38 0
MCP-1 0.11 (0.04) 0.94 (0.09) 80.06 0
IFN-
 0.009 (0.004) 0.26 (0.06) 18.91 0
TNF-	 0.004 (0.001) 0.01 (0.00) 15.02 .001
MIP-1	 0.05 (0.01) 0.36 (0.06) 23.08 0
MIP-1 0.12 (0.01) 0.22 (0.03) 7.70 .011
TGF-1* 0.10 (0.01) 0.26 (0.02) 22.55 0
SE, Standard error;G-CSF, granulocyte colony-stimulating factor;GM-CSF,
granulocyte macrophage colony stimulating factor.
*Anti-inflammatory.pro-inflammatory cells in a newly created wound bed re-sults in delayed healing.26-28 Hubner et al29 showed a
strong and early induction of pro-inflammatory cytokines
following cutaneous injury. This induction was significantly
reduced in healing-impaired glucocorticoid-treated mice.
Consistent with multiple other studies, our data also indi-
cates that the quantity of pro-inflammatory cytokines is
significantly diminished in the tissue of rapid healers. We
believe that CVI ulcer delayed healers have wounds that
cannotmount an appropriate initial inflammatory response;
thus, the prolonged cellular effects of inflammation are not
propagated.
In comparison to healthy tissue samples, inflammatory
cytokines, in addition to TGF-1, were significantly ele-
ssed as pg/ug protein)
lcer before therapy Ulcer after therapy
Mean SD N Mean SD
0.89 1.72 30 0.28 0.24
0.17 0.27 30 0.03 0.04
16.38 13.27 30 20.13 20.1
0.03 0.04 30 0.02 0.03
1.27 1.7 30 0.62 0.8
15.18 21.89 30 3.80 4.78
0.04 0.05 30 0.04 0.06
1.65 1.68 30 0.85 0.78
0.05 0.04 30 0.04 0.03
0.27 0.28 30 0.14 0.16
0.07 0.07 30 0.02 0.04
1.03 0.55 30 0.94 0.58
0.27 0.27 30 0.14 0.16
0.02 0.03 30 0.01 0.01
0.54 1.02 30 0.24 0.15
0.32 0.5 30 0.19 0.11
0.24 0.07 10 0.34 0.12
r; GM-CSF, granulocyte macrophage colony stimulating factor.
Table V. Cytokines demonstrating significant differences
in ulcer tissue before compression compared to ulcer
tissue after 4 weeks of compression therapy (pg/ug
protein). All cytokines, except TGF-1, n  30. TGF-1
n  10
Before therapy After therapy
Cytokines Mean (SE) Mean (SE) F-Statistic
P
Value
IL-1	 0.89 (0.31) 0.28 (0.04) 4.40 .045
IL-1 0.17 (0.05) 0.03 (0.01) 8.54 .007
IL-6 1.27 (0.31) 0.62 (0.15) 6.94 .013
IL-8 15.18 (4) 3.80 (0.87) 7.06 .013
IL-12p40 1.65 (0.31) 0.85 (0.14) 6.58 .016
G-CSF 0.27 (0.05) 0.14 (0.03) 4.63 .04
GM-CSF 0.07 (0.01) 0.02 (0.01) 12.41 .001
IFN-
 0.27 (0.05) 0.14 (0.03) 8.94 .006
TNF-	 0.02 (0.01) 0.01 (0) 4.18 .05
TGF-1 0.24 (0.02) 0.34 (0.04) 5.14 .031
SE, Standard error;G-CSF, granulocyte colony-stimulating factor;GM-CSF,
granulocyte macrophage colony stimulating factor.xpre
U
g factovated in ulcer tissue before multilayer compression therapy.
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treated CVI ulcer tissue than in healthy tissue. IL-1 is a
pleiotropic cytokine, and previous studies have reported
that IL-1	 is present in lower levels in acute wound fluid
when compared to fluid from chronic wounds.30
In our study, treatment of CVI ulcers with 4 weeks of
compression therapy resulted in a decrease in the levels of
the majority of the pro-inflammatory ulcer cytokines. Tren-
gove et al31 reported that the pro-inflammatory cytokines
IL-1, IL-6, and TNF-	 have significantly higher levels in
the fluid of non-healing wounds. In their study, in vitro
fibroblast proliferative response was stunted when this non-
healing wound fluid was added to cultures; thus, healing
may be impaired by specific inflammatory mediators.
Several of the proteins studied in this project have
known anti-inflammatory properties, including TGF-1,
IL-10, and IL-1 Ra. TGF-1 levels in ulcer tissue were
significantly increased after 4 weeks of sustained compres-
sion therapy. TGF-1 has been reported to regulate dermal
tissue fibrosis, although the addition of TGF-1 to venous
ulcer fibroblasts has not been shown to induce prolifera-
tion.32,33 Likewise, the potent anti-inflammatory cytokine
IL-10 had higher levels following compression which ap-
proached statistical significance (P  .076).
Rapidly healing wounds were associated with higher
levels of pro-inflammatory cytokines in the ulcer tissue at
initial presentation before compression treatment. Five
pro-inflammatory cytokines displayed this significant
finding, including IL-1	, IL-1, IFN-
, IL-12p40, and
GM-CSF. Elevated expression of these cytokines may
indicate that a wound has mounted and maintained an
appropriate level of defensive mechanisms and is pre-
pared for future coordinated cellular repair. Our data
indicates that although delayed-healing CVI ulcers con-
tain inflammatory proteins, these cytokines were present
at significantly lower levels, perhaps due to increased
cellular senescence.
Importantly, the rapid healing ulcers not only had very
high pre-compression levels of IFN-
 but also had a signif-
icant reduction in this cytokine following compression
Table VI. Cytokines displaying significantly different
protein levels in rapid (healed 40%) compared to
delayed (healed 40%) healers (pg/ug protein)
Healed 40% Healed 40%
Cytokines Mean SD Mean SD Compression
P
value
IL-1	 1.43 2.3 0.35 0.30 Before .02
IL-1 0.26 0.34 0.08 0.14 Before .03
IFN-
 0.42 0.25 0.12 0.20 Before .001
IL-12p40 2.24 1.8 0.93 1.2 Before .01
GM-CSF 0.11 0.08 0.04 0.04 Before .02
IL-1 Ra* 25.3 18.6 15 13.5 After .02
SD, Standard deviation;GM-CSF, granulocyte macrophage colony stimulat-
ing factor.
*Anti-inflammatory.therapy. IFN-
 is a glycoprotein with numerous immuno-logical functions. IFN-
 has been shown to suppress nu-
merous genes responsible for the cell cycle, DNA replica-
tion, and RNA metabolism of keratinocytes; thus, it is
thought to increase host defense against viruses by denying
access into cells in which to replicate.34 Konur et al35 has
shown that IFN-
 is the key mediator in keratinocyte
apoptosis. IFN-
 is also a positive regulator for the produc-
tion of TNF-	 from keratinocytes, and it acts synergistically
with IL-1	 to produce TNF-	.36 Administration of recom-
binant murine IFN-
 to mice with surgically created inci-
sions caused significant impairment in wound healing.37
Likewise, multiple sclerosis patients receiving injections of
interferon have experienced skin inflammation and skin
breakdown.38,39 Data suggests that IFN-
 expression is
important during the inflammatory phase of acute wound
healing.
We believe that up-regulation of pro-inflammatory
cytokines at baseline may be a marker for healthier
peri-wound tissue that has better potential to heal. How-
ever, it is similarly important for up-regulated cytokine
levels to be controlled to allow resumption of healing.
We agree with the hypothesis previously proposed by
Simka40 that an anti-IFN-
 agent may have a significant
clinical impact on the treatment of CVI ulceration, and
anti-interferon therapy is already used to treat a variety of
diseases.
Rapid healers also expressed a significantly higher level
of IL-1 Ra in ulcer tissue compared to delayed healers after
compression therapy. This suggests that up-regulation of
anti-inflammatory cytokines is important during treatment
to support the healing process. Mice homozygous for a null
mutation in the gene encoding IL-1 Ra develop lethal
arterial inflammation.41 An imbalance between IL-1 Ra
and IL-1 also predisposes patients to inflammatory arthritis
and arteritis forming the basis for the treatment of resistant
cases of rheumatoid arthritis with IL-1 Ra (Anakinra; Am-
gen, Thousand Oaks, Calif).42
This study has significant limitations that must be
considered during interpretation of the data. With a
study population of 30 limbs, subset analysis is not
possible for patient demographics and risk factors, and
some relevant associations between cytokine levels and
outcomes may be missed due to a lack of power. Also,
when studying a panel of 22 predictors, it is possible that
any positive finding may be related to chance. Therefore,
we believe that further studies in human tissue in this
population and in populations with other types of non-
healing ulcers are required to strengthen the associations
outlined in this manuscript.
CONCLUSION
The results of this study indicate that CVI ulcers have
high levels of inflammatory proteins prior to compression
therapy. Importantly, rapidly healing ulcers likely need an
elevated level of pro-inflammatory cytokines, including IL-
1	, IL-1, IFN-
, IL-12p40, and GM-CSF within the
ulcer bed before initiating compression therapy. Compres-
sion therapy is associated with a reduction in the pro-
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, and
promotes anti-inflammatory proteins. This data suggests
that cytokines may provide targets in which inhibition or
promotion at appropriate time points in the healing process
may provide novel therapeutic approaches to CVI ulcer
Fig. Levels of cytokine in ulcer tissue before and after 4
compared to ulcers that healed 40% at 4 weeks. A
C, Interleukin-1 (IL-1), D, Interleukin-1 recepto
F, Granulocyte macrophage colony stimulating factor
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